Pharmacokinetic study of mangiferin in rat plasma and retina using high-performance liquid chromatography by Hou, Yunlong et al.
Pharmacokinetic study of mangiferin in rat plasma and retina
using high-performance liquid chromatography
Yunlong Hou,2 Shengjun Fan,2 Hong Zhang,1 Yuanqin Gu,2 Xuhui Yu,1 Baoxin Li1
(The first two authors contributed equally to this work)
1Eye hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China; 2Department of Pharmacology,
Harbin Medical University, Harbin, P.R. China
Purpose: Although the naturally occurring antioxidant mangiferin has been widely used, it is not yet known whether it
can cross the blood-retina barrier (BRB) and enter the eye. The purpose of this experiment was to investigate the ability
of mangiferin to pass the blood-retina barrier.
Methods: Sprague–Dawley rats were used for biologic fluid sampling after intravenous administration of mangiferin at
doses of 10, 25, and 50 mg/kg. Blood and retina samples were collected at different time points post-dose. High-
performance liquid chromatography (HPLC) separation was conducted on a COSMOSIL 5C18—MS—II column (4.6
mm×250 mm, 5 μm) with a flow rate of 1.0 ml/min using a mobile phase comprised of methanol −2% glacial acetic acid
(40:60 v:v).
Results: The HPLC method has proven suitable to determine the presence of mangiferin in the eye. The plasma
concentration of mangiferin was dose dependent. Pharmacokinetic parameters of mangiferin in plasma after intravenous
administration were fitted to the two-compartment model with the first-order elimination and first-order transfer between
central and peripheral compartments. The concentration of mangiferin in the retina goes with that in the blood. Mangiferin
concentrations in the retina reached 5.69±1.48 μg/ml 0.5 h after intravenous administration (50 mg/kg) and then dropped
gradually to 0.30±0.02 μg/ml 5.0 h later. The eye–to-plasma concentration ratio was 2.80%.
Conclusions: Mangiferin can pass the blood-retina barrier after a single intravenous administration and may be a potential
natural antioxidant in treating eye diseases.
The protective role of naturally occurring antioxidants
has recently been a focus of attention. Mangiferin, 1,3,6,7-
tetrahydroxyxanthone-C-2-β-D-glucoside (Figure 1), is one
such naturally occurring polyphenol [1] that is widely found
in many herbs such as Anemarrhena asphodeloides Bung
(Chinese herbal name: Zhi-Mu) [2] and Mangifera indica
[3].  Due  to  its  antioxidant  [4],  anti-apoptotic  [5],
immunomodulating  [6]  and  anti-diabetic  potential  [7],
mangiferin may have a putative role in treating certain eye
diseases, such as age-related macular degeneration (AMD),
cataracts and diabetic retinopathy [8,9]. However, whether
mangiferin  can  pass  the  blood-ocular  barrier  remains
unknown. Before mangiferin is applied in the treatment of eye
diseases,  it  is  necessary  to  know  the  pharmacokinetic
parameters of mangiferin in the eye.
The eye is a unique organ with a blood-retina barrier
(BRB) [10]. This barrier is relatively impermeable, like the
blood–brain barrier (BBB), controls the passage of substances
from the blood into the eye and normally keeps most drugs
out of the eye [11]. Although many published papers have
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described the bioanalysis of mangiferin in plasma and urine
[12–16],  very  few  reports  exist  assessing  the  amount  of
mangiferin allowed into the eye. This paper investigated the
ability of mangiferin to pass the BRB and provided a limited
pharmacokinetic study of mangiferin in the eye.
METHODS
Reagents  and  chemicals:  Mangiferin  and  4-Nitrophenol,
which was used as an internal standard (I.S.), were purchased
from  Sigma  (Sigma-Aldrich,  Tokyo,  Japan).  The
chromatographic solvents and reagents were obtained from
the National Institute for the Control of Pharmaceutical and
Figure  1.  Chemical  structure  of  mangiferin  (1,3,6,7-
tetrahydroxyxanthone-C-2-β-D-glucoside).
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1659Biologic Products (Beijing, China). All substances were of
chromatographic grade. De-ionized water was prepared using
a  Milli-Q  water  purifying  system  from  Millipore  Corp.
(Bedford, MA).
Animal  treatment:  Adult  male  Sprague–Dawley  rats
(280~320 g) were supplied by the Animal Research Center at
Harbin Medical University (Harbin, Heilongjiang Province,
China). The rats were specifically pathogen-free and housed
in a limited access rodent facility for at least 5 days. The room
controls were set to maintain the temperature at 22 °C±2 °C,
the relative humidity at 55%±15%, the illumination intensity
at 150~300 lx, an air ventilation frequency of 15~20 times/h,
and a 12 h illumination period (07:00~19:00) each day. The
animals drank sterilized drinking water, and standard chow
diet  was  supplied  ad  libitum  to  each  cage.  The  animal
experiments were performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research,  and  were  approved  by  the  Animal  Ethics
Committee of Harbin Medical University.
Preparation  of  standard  and  internal  standard  stock
solutions:  The  standard  stock  solution  was  prepared  by
dissolving 10 mg of mangiferin in a 10 ml methanol to obtain
a nominal concentration of 1,000 μg/ml. The internal standard
(I.S.) stock solution was prepared by dissolving 0.20 mg of 4-
Nitrophenol  in  100  ml  of  methanol  to  obtain  a  nominal
concentration  of  2  μg/ml.  All  the  stock  solutions  were
maintained at 4 °C until use.
Preparation of assay standard samples: Mangiferin standard
samples of plasma (0.50, 1.00, 5.00, 10.00, 20.00, 50.00,
100.00, and 150.00 μg/ml) were prepared by spiking control
rat plasma with appropriate amounts of the standard stock
solution prepared above. Quality control (QC) samples were
used to determine accuracy and precision of the method, and
were independently prepared at low (1.00 μg/ml), medium
(10.00 μg/ml) and high (100.00 μg/ml) concentrations in the
same manner. The I.S. was added to each standard sample
immediately before sample processing. All the samples were
stored at −20 °C until analysis.
Mangiferin standard samples of eyes (0.10, 0.50, 1.00,
2.00, 4.00, 6.00, 8.00, and 10.00 μg/ml) were prepared by
spiking control rat eye samples with appropriate amounts of
the standard stock solution prepared above. QC samples were
used to determine accuracy and precision of the method, and
were independently prepared at low (0.50 μg/ml), medium
(2.00 μg/ml) and high (8.00 μg/ml) concentrations in the same
manner.  The  I.S.  was  added  to  each  standard  sample
immediately before sample processing. All the samples were
stored at −20 °C until analysis.
Extraction procedure: Each rat (n=6) was fasted for 24 h with
free  water  during  the  experiment.  Then,  they  were
intravenously  administrated  of  mangiferin,  which  was
suspended in 2 ml of dimethyl sulphoxide (10, 25, and 50 mg/
kg).
Blood samples (200 μl) collected from the cervical artery
at 0.5, 1.0, 1.5, 2, 2.5, 3.5, 4.5, 5.5, 7.5, 9.5, 11.5, and 24 h
post-dose  were  seated  for  approximately  30  min  and
centrifuged at 4,000xg for 20 min to separate the plasma
supernatant. To 100 μl of plasma, 100 μl of I.S. solution
(2  μg/ml)  and  400  μl  of  acetonitrile-glacial  acetic  acida
(9:1,v:v) were added. Each tube was mixed thoroughly by
vortexing for 90 s. After centrifugation for 10 min at 3,000 xg,
the supernatant was transferred into labeled, clean test tubes
and evaporated to dryness in a water bath at 50 °C under a
stream of nitrogen. The residues were reconstituted in 100 μl
of mobile phase with vortexing for 90 s, and the centrifugation
procedure  was  repeated.  Standard  and  QC  samples  were
prepared  following  the  method  described  above.  A  20  μl
aliquot was then injected onto the chromatographic column.
As to eye samples, samples from both eyes were collected
at 0.5, 1.0, 1.5, 2, 2.5, 3.5, 4.5, 5.5, and 7.5 h post-dose and
placed in a normal saline solution to remove blood and the
conjunctiva. The eyes were then cut from the equator, and the
lens and vitreous were removed. The retina was carefully
dissected  from  the  choroid  and  optic  nerve,  and  the
homogenate  was  prepared.  Briefly,  retina  samples  were
weighed and homogenized in acetonitrile at 0 °C using an
FJ-2000 homogenizer (Biaoben Model Factory, Shanghai,
China). The homogenates were then ultrasonically extracted
using a Branson Sonifier 150D (Branson, Danbury, CT) and
centrifuged at 1,000× g for 10 min. The supernatants were
taken out and transferred into labeled, clean test tubes. To
100 μl of supernatant, 100 μl of I.S. solution (2 μg/ml) and
400 μl of acetonitrile-glacial acetic acida (9:1, v:v) were added
and  mixed  thoroughly  by  vortexing  for  90  s.  After
centrifugation, the supernatant was transferred into labeled,
clean test tubes evaporated to dryness in a water bath at 50 °C
under a stream of nitrogen. The residues were reconstituted in
100  μl  of  mobile  phase  with  vortexing  for  90  s,  and  the
centrifugation  procedure  was  repeated.  Standard  and  QC
samples were prepared following the method described above.
A 20 μl aliquot was then injected onto the chromatographic
column.
Assay conditions: HPLC separation was performed using the
Agilent 1200 Series Rapid Resolution system. A COSMOSIL
5C18—MS—IIanalytical column (4.6 mm×250 mm, 5 μm,
Nacalai Tesque, Inc., Kyoto Japan) was used and operated at
25 °C. The mobile phase consisted of methanol −2% glacial
acetic acid (40:60,v:v) and was delivered by a G1322A pump
at a flow-rate of 1.0 ml/min. The G1315BDIO diode array
detector was set at 318 nm and all the measurements were
performed at 35 °C. A HP1090 chromatographic work station
was used for data acquisition. The sensitivity was 0.2 AUFS.
Method  validation:  Method  validation  and  documentation
were performed according to guidelines set by the United
States Food and Drug Administration (FDA) for bioanalytical
method validation [2].
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Figure  2.  HPLC  chromatograms  of  plasma  mangiferin.  HPLC
separation was performed on plasma samples using the Agilent 1200
Series  Rapid  Resolution  system.  A  COSMOSIL  5C18—MS—
IIanalytical column (4.6 mm×250 mm,5 μm) was used and operated
at 25 °C. The mobile phase consisted of methanol −2% glacial acetic
acid (40:60 v:v). Typical chromatograms of blank plasma, blank
plasma spiked with mangiferin and I.S., and rat plasma sample after
injection of mangiferin are presented. Mangiferin and the I.S. were
eluted at 5.6 and 12.16 min, respectively. The total run time was less
than 30 min. A good separation of the I.S. and mangiferin was
obtained under the specified chromatographic conditions. There is
no disturbance from the background signals in the plasma after the
protein precipitation step. A: Typical chromatogram of blank plasma.
B. Typical chromatogram of blank plasma spiked with standard
mangiferin (5 μg/ml) and I.S. panel. C. Typical chromatogram of
blood sample containing mangiferin (24.14 µg/ml) collected at 0.5 h
after  mangiferin  administration  (10  mg/kg,  i.v.).  D:  Typical
chromatogram of blood sample containing mangiferin (73.88 µg/ml)
collected at 0.5 h after mangiferin administration (25 mg/kg, i.v.).
E: Typical chromatogram of blood sample containing mangiferin
(221.54 µg/ml) collected at 0.5 h after mangiferin administration (50
mg/kg, i.v.).
the standard calibration curve, the analyses of mangiferin in
plasma and eye samples were performed on three independent
days using fresh preparations. The calibration curves were
prepared over a linear range of 0.50~150.00 μg/ml for plasma
and 0.10~10.00 μg/ml for eye samples. Each calibration curve
consisted  of  a  double  blank  sample  (without  internal
standard), a blank sample (with internal standard) and eight
calibrator concentrations.
Each calibration curve was constructed by plotting the analyte
to  internal  standard  peak  area  ratio  (y)  against  analyte
concentrations (x). The calibration curves were fitted using a
least square linear regression model y=ax + b, weighted by 1/
x2  (the  reciprocal  of  the  square  of  the  mangiferin
concentration) using the Analyst® software. The resulting a,
Figure 3. HPLC chromatograms of mangiferin in the eye. HPLC
separation  was  performed  using  the  Agilent  1200  Series  Rapid
Resolution system. A COSMOSIL 5C18—MS—IIanalytical column
(4.6 mm×250 mm, 5 μm) was used and operated at 25 °C. The mobile
phase consisted of methanol −2% glacial acetic acid (40:60,v:v).
Typical  chromatograms  of  blank  eye,  blank  eye  spiked  with
mangiferin and I.S., and rat eye sample after injection of mangiferin
are presented. Mangiferin and the I.S. were eluted at 5.6 and 12.16
min, respectively. The total run time was less than 30 min. A good
separation of the I.S. and mangiferin was obtained under the specified
chromatographic  conditions.  There  is  no  disturbance  from  the
background signals in the eye after the protein precipitation step.
A:  Typical  chromatogram  of  blank  eye  sample.  B:  Typical
chromatogram of blank eye sample spiked with standard mangiferin
(1  μg/ml)  and  I.S.  C:  Typical  chromatogram  of  eye  sample
containing mangiferin (5.63 µg/ml) collected at 1 h after mangiferin
administration (50 mg/kg, i.v.).
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concentrations, which were then statistically evaluated. All
calibration curves of mangiferin were constructed before the
experiments with correlation values of at least 0.995.
Specificity: The specificity was defined as: non-interference
when mangiferin was being retained from the endogenous
plasma  components  and  eye  samples,  and  no  cross-
interference between mangiferin and internal standard using
the proposed extraction procedure and HPLC conditions. Six
different  lots  of  blank  (mangiferin-free  plasma)  were
evaluated both with and without internal standard to assess the
specificity of the method.
Accuracy and precision: The intra- and inter-assay accuracies
were  expressed  as  the  percentage  difference  between  the
measured concentration and the nominal concentration. Intra-
assay precision and accuracy were calculated using replicate
(n=6) determinations for each concentration of the spiked
plasma  sample  during  a  single  analytical  run.  Inter-assay
precision and accuracy were calculated using replicate (n=6)
determinations of each concentration made on three separate
days.  Accuracy  (%  Bias)=[(Cobs  -Cnom)/Cnom]  ×  100.  The
precision (relative standard deviation; RSD) was calculated
from the observed concentrations as follows: RSD=[standard
deviation  (SD)/Cobs]  ×100.  Accuracy  (Bias)  and  precision
(RSD)  values  within  ±15%,  covering  the  range  of  actual
experimental concentrations, were considered acceptable [2].
Recovery (extraction efficiency): The extraction efficiency of
mangiferin was determined by analyzing replicate sets (n=6)
of QC samples: 1.00, 10.00, and 100.00 μg/ml for rat plasma
and 0.50, 2.00, and 8.00 μg/ml for rat eyes, representing low,
medium and high QCs, respectively. Recovery was calculated
by comparing the peak areas of mangiferin added into blank
samples  and  extracted  using  the  protein  precipitation
procedure,  with  those  obtained  from  mangiferin  spiked
directly into post-protein precipitation solvent at three QC
concentration levels.
Stability study: The stability of mangiferin in rat plasma and
rat eyes was assessed by analyzing replicates (n=6) of QC
samples at concentrations of 1.00, 10.00, and 100.00 μg/ml
for rat plasma and 0.50, 2.00, and 8.00 μg/ml for rat eyes. The
investigation covered expected conditions during all of the
sample  storage  and  process  periods,  which  included  the
stability data from freeze/thaw, bench-top, autosampler and
long-term  stability  tests.  For  all  stability  studies,  freshly
prepared and stability testing QC samples were evaluated by
using freshly prepared standard curves for the measurement.
The concentrations obtained from all stability studies were
compared with the freshly prepared QC samples, and the
percentage  concentration  deviation  was  calculated.  The
analytes were considered stable in mouse plasma and eye
when  the  concentration  difference  between  the  freshly
prepared samples and the stability testing samples was less
than 15%.
Pharmacokinetic analysis: To evaluate the suitability of the
assay for pharmacokinetic studies, 10, 25 or 50 mg/kg of
mangiferin  were  intravenously  administered  to  rats.  Six
animals  were  used  in  each  dosage.  Pharmacokinetic
calculations were performed using the observed data. All data
were  subsequently  processed  using  the  DAS  2.0  program
(Drug and Statistics 2.0). All values obtained were expressed
in mean±standard deviation.
RESULTS
Method validation:
Linearity and sensitivity—The method was validated
using the criteria described above. The data were found to be
linear over a concentration range of 0.50~150.00 μg/ml in
blood  samples  and  a  range  of  0.10~10.00  μg/ml  in  eye
samples. The regression equation for plasma was y=0.1637x
- 0.2481, with the correlation coefficient r=0.9993, while the
eye standard curve was described by the equation y=0.2832 x
+  0.0280,  with  r=0.9994.  If  r>0.999,  it  indicated  good
linearity. The limit of quantitation (LOQ) was 0.50 μg/ml for
plasma and 0.10 μg/ml for eye, which can be determined with
a relative error (RE) and precision (RSD) of <20% at a signal-
to-noise  ratio  of  3.  The  limits  of  detection  (LOD)  were
0.20 μg/ml and 0.10 μg/ml for plasma and eye, based on a
signal to noise ratio of 3.
Specificity—Under this chromatographic condition, the
number of theoretical plates was 7,000 and the resolution of
mangiferin was 115 peaks/min. The degree of interference by
endogenous plasma or eye constituents with mangiferin and
I.S. was assessed by inspection of chromatograms derived
from a processed blank plasma sample or blank eye sample.
Typical chromatograms of blank plasma, blank plasma spiked
with mangiferin and I.S. and rat plasma sample after injection
of  mangiferin  are  presented  in  Figure  2.  Typical
chromatograms of blank eye sample, blank eye sample spiked
with mangiferin and I.S. and rat eye sample after injection of
mangiferin are presented in Figure 3. Mangiferin and I.S. were
eluted at 5.6 and 12.16 min, respectively. The total run time
was less than 30 min. A good separation of I.S. and mangiferin
was obtained under the specified chromatographic conditions.
There is no disturbance from the background signals either in
the plasma or the eye samples after the protein precipitation
step, which can be seen from Figure 2 and Figure 3.
Accuracy,  precision,  recovery,  and  stability—The
accuracies for intra- and inter-day assay, the recoveries and
the  stability  of  mangiferin  were  estimated  at  three
concentrations (1.00, 10.00, and 100.00 μg/ml for rat plasma
and 0.50, 2.00, and 8.00 μg/ml for rat eye). As shown in Table
1, the intra-day and inter-day precisions (% RSD) in rat plasma
and  eye  were  <15%.  The  recovery  was  approximately
82.47%–93.34% in the plasma and 90.91%–97.00% in the
eye, as is shown in Table 2. The stability of mangiferin are
shown  in  Table  3.  The  precision  for  freeze/thaw  samples
ranged from 3.81−8.26% for plasma and 2.72%–9.38% for
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plasma  and  99.56%–108.75%  for  eye,  respectively.  The
results indicated that mangiferin was stable in either plasma
or eye for three cycles when stored at −20 °C and thawed to
room  temperature.  The  precision  for  bench-top  stability
ranged from 3.32−8.54% for plasma and 7.48%–10.26% for
eye, and the accuracy ranged from 90.69−99.58% for plasma
and  94.29%–98.35%  for  eye,  respectively.  This  indicates
reliable stability under the experimental conditions of the
analytical runs. The precision and accuracy for long-term
stability  samples  ranged  from  3.84−7.92%  and  92.51%–
101.38% for plasma and 4.03−8.25% and 99.16%–105.54%
for eye, respectively. The results of long-term storage stability
data indicated that the plasma and eye samples were stable at
−20 °C for over 1 month. The precision for the autosampler
stability ranged from 4.97%–6.31% for plasma and 2.38%–
6.43% for eye, and the accuracy ranged from 89.35%–92.59%
for plasma and 91.24%–96.67% for eye, respectively. The
result suggested that mangiferin could be analyzed for over 8
h in the autosampler tray at 4 °C with acceptable levels of
precision and accuracy. The results of stability experiments
showed that no stability-related problems occurred during
sample storage, extraction or chromatography processes for
mangiferin in plasma and eye samples.
TABLE 1. INTRA- AND INTER-DAY PRECISION AND ACCURACY OF MANGIFERIN IN RAT PLASMA AND EYE (N=6).
Matrix Nominal
concentration
(μg/ml)
Observed
concentration
(μg/ml)±SD
Accuracy (% bias) RSD (%)
Plasma Intra-day (n=6) 1 0.96+0.08 −4 8.33
10 9.89±0.51 −1.1 5.15
100 99.62±6.80 −0.4 6.82
Inter-day(n=6) 1 0.94±0.08 −6 8.51
10 10.02±1.01 2 10.31
100 99.48±0.08 −0.5 0.08
Eye Intra-day(n=6) 0.5 0.49±0.04 −2 8.16
2 2.02±0.18 2 9.09
8 7.97±0.19 −0.4 2.38
Inter-day(n=6) 0.5 0.48±0.04 −4 8.33
2 1.95±0.23 −2.5 11.79
8 8.01±0.08 0.1 1.01
The intra- and inter-assay accuracies were expressed as the percent difference between the measured concentration and the
nominal concentration. Intra-assay precision and accuracy were calculated using replicate (n=6) determinations for each
concentration of the spiked plasma sample during a single analytical run. Inter-assay precision and accuracy were calculated
using replicate (n=6) determinations of each concentration made on three separate days. Accuracy (% Bias)=[(Cobs  -C nom) /
Cnom]×100.The precision (relative standard deviation; RSD) was calculated from the observed concentrations as follows:
RSD=[standard deviation (SD) / Cobs] ×100. Accuracy (Bias) and precision (RSD) values within ±15% covering the range of
actual experimental concentrations were considered acceptable [2].
TABLE 2. RECOVERY OF MANGIFERIN FROM RAT PLASMA AND EYE (N=6).
Matrix Spiked concentration (μg/ml) Recovery (%±SD) RSD (%±SD)
Plasma 1 0.825±0.05 6.4
10 0.832±0.11 13.6
100 0.931±0.15 14.9
Eye 0.5 0.911±0.24 5.8
2 0.969±0.06 7
8 0.923±0.14 14.7
The extraction efficiency of mangiferin was determined by analyzing replicate sets (n=6) of QC samples: 1.00,10.00, and 100.00
μg/ml for  rat plasma and 0.50, 2.00, and 8.00 μg/ml for rat eye, representing low, medium, and high QCs, respectively. Recovery
was calculated by comparing the peak areas of mangiferin added into blank samples and extracted using the protein precipitation
procedure with those obtained from mangiferin spiked directly into post-protein precipitation solvent at three QC concentration
levels.
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technique and liquid chromatographic detection were then
applied  to  the  pharmacokinetic  characterization  using  the
DAS 2.0 program (Drug and Statistics 2.0, Hefei, China).
After a single intravenous administration of 10, 25, or 50 mg/
kg of mangiferin, the concentration-time data conformed to a
two-compartment model and the major parameters correlated
positively with the dosage given. The dosages for Cmax were
24.75±0.85,  56.77±21.13,  and  200.77±32.12  μg/ml,
respectively,  for  AUC(0-t),  they  were  121.48±12.92,
205.28±104.30,  and  577.71±63.30l  μg/ml/h,  respectively.
The pharmacokinetic parameters are listed in Table 4. The
mean  plasma  concentration–time  profile  is  illustrated  in
Figure 4. Results of the study are consistent with the works
by Lai [17] and with other previously published studies [12–
16]. Detectable mangiferin was found in the eye, as shown in
Table 5.The mangiferin concentration reached 5.69±1.48 μg/
ml 0.5 h after intravenous administration (50 mg/kg) and then
dropped  gradually  to  0.30±0.02  μg/ml  5.0h  later.  The
pharmacokinetic parameters of the retina are listed in Table
6.
DISCUSSION
For the first time, our study showed that mangiferin can cross
the  blood-retina  barrier  after  a  single  intravenous
administration. The study also showed that the HPLC method
is suitable for detecting mangiferin in the eye.
HPLC  has  been  widely  used  in  the  detection  of
mangiferin in herbs as well as biologic fluids [12,13,15,16,
TABLE 3. STABILITY DATA FOR MANGIFERIN UNDER VARIOUS CONDITIONS (N=6)
Tissue Storage period and storage condition Nominal
Concentration
(µg/ml)
Observed
concentration (µg/
ml)±SD
Accuracy
(%)
RSD
(%)
Plasma 3 Freeze/thaw cycles(−20 °C) 1 1.06±0.06 107.56 8.26
10 10.9±0.24 110.25 3.81
100 102.12±5.30 102.01 5.65
Process sample stability (RT; 8 h) 1 0.98±0.65 99.58 8.54
10 9.86±0.73 98.75 3.32
100 90.48±0.59 90.69 7.15
Long-term stability (−20 °C; One month) 1 0.96±0.08 97.18 7.92
10 9.19±0.84 92.51 6.39
100 100.82±0.13 101.38 3.84
Autosampler stability (4 °C; 8 h) 1 0.91±0.31 91.44 5.24
10 9.31±0.74 92.59 6.31
100 89.43±0.21 89.35 4.97
Eye 3 Freeze /thaw cycles (−20 °C) 0.5 0.50±0.94 108.75 9.38
2 1.98±0.54 99.56 3.45
8 8.01±0.16 102.79 2.72
Process sample stability (RT; 8 h) 0.5 0.46±0.06 95.37 8.68
2 1.97±0.32 94.29 10.26
8 7.98±0.16 98.35 7.4
Long-term stability (−20 °C; One month) 0.5 0.51±0.29 105.54 6.51
2 2.02±0.08 101.32 8.25
8 7.99±0.11 99.16 4.03
Autosampler stability (4 °C; 8 h) 0.5 0.47±0.69 91.24 2.38
2 1.96±0.37 96.67 4.76
8 7.87±0.46 92.54 6.43
The stability of mangiferin in rat plasma and eye were assessed by analyzing replicates (n=6) of QC samples at concentrations
of 1.00, 10.00, and 100.00 μg/ml for rat plasma and 0.50, 2.00, and 8.00 μg/ml for rat eye. The investigation covered expected
conditions during all of the sample storage and process periods, which included the stability data from freeze/thaw, bench-top,
autosampler and long-term stability tests. For all stability studies, freshly prepared and stability testing QC samples were
evaluated by using freshly prepared standard curve for the measurement. The concentrations obtained from all stability studies
were compared with the freshly prepared QC samples, and the percentage concentration deviation was calculated. The analytes
were considered stable in mouse plasma and eye when the concentration difference was less than 15% between the freshly
prepared samples and the stability testing samples.
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166418,19].  However,  whether  it  is  applicable  to  the
pharmacokinetic  study  of  mangiferin  in  the  eye  remains
unknown. The limit of quantification (LOQ) was defined as
the lowest drug concentration that can be determined with a
relative error (RE) and precision (RSD) of <20% at a signal-
to-noise ratio of 3. In practice, this is the lowest concentration
in the calibration curve. The LOQ in this study was 0.50 μg/
ml for plasma and 0.10 μg/ml for eye, respectively. The LOQ
for  both  eye  and  plasma  samples  was  sufficient  for
pharmacokinetic  studies  of  mangiferin.  The  eye  tissue
contains  an  abundance  of  protein,  and  thus  the
deproteinization  is  important  in  the  pre-treatment  of  eye
tissues. In this study, we tried pre-treating the eye sample
using  the  standard  method,  but  results  showed  that  an
extremely low amount of mangiferin was detected.
A further study indicated that most of the compound
remained in the eye tissue, indicating that mangiferin may
possess a high protein-binding affinity. Therefore, we adopted
homogenization and ultrasonic extraction with acetonitrile to
obtain  a  high  amount  of  mangiferin  from  the  eye  tissue.
Acetonitrile-acetic acid (9:1, v/v) was then used in protein-
precipitating to pre-treat both the plasma and eye samples
before HPLC. The background signal of plasma or eye had
little or no effect on the HPLC separation conditions after the
simple protein precipitation clean-up step. The above results
have shown that HPLC is an appropriate method to study the
pharmokinetic  parameters  of  mangiferin  in  the  eye  with
adequate sensitivity, selectivity and accuracy.
The  blood-brain  barrier  (BBB)  is  a  separation  of
circulating blood and cerebrospinal fluid (CSF) maintained by
the choroid plexus in the central nervous system (CNS) [20].
Much like the brain, the eye has evolved cellular barriers to
exclude  potentially  harmful  blood-borne  agents  while
allowing passage of nutrients to ensure proper functioning.
The barrier is known as the blood-retina barrier (BRB), which
separates the retina and other contents from the fenestrated
TABLE 4. PHARMACOKINETIC PARAMETERS OF PLASMA FOLLOWING MANGIFERIN ADMINISTRATION (10, 25, AND 50 MG/KG, I.V.) BY
DRUG AND STATISTICS 2.0
Parameters 10 mg/kg 25 mg/kg 50 mg/kg
Tmax (h) 0.75±0.27 0.58 ±0.20 0.50±0.01
Cmax (μg/ml) 24.75±0.85 56.77±21.13 200.77±32.12
t1/2α (h) 2.15±0.81 1.60±0.28 0.81±0.60
t1/2β (h) 3.12±0.04 1.61±0.31 3.25±1.82
AUC0-t (μg/ml·h−1) 121.48±12.92 205.28±104.30 577.71±63.30
K21 (h−1) 0.09±0.10 0.37±0.19 0.60±0.57
K10 (h−1) 0.18±0.01 0.35±0.05 0.58±0.37
K12 (h−1) 0.17±0.10 0.22±0.25 1.28±1.90
MRT0-t (h) 5.89±0.06 4.23±0.66 3.10±0.23
CL (L/kg·h−1) 0.06±0.01 0.13±0.06 0.07 ±0.01
The concentration-time data after single intravenous administration of 10, 25 or 50 mg/kg of mangiferin conformed to a two-
compartment model. Tmax: time of the maximum plasma concentration; Cmax: maximum plasma concentration following drug
administration; t1/2(α): distribution half-life; t1/2(β): elimination half-life; AUC: area under the plasma concentration–time curve;
K10 : first order elimination from compartment 1; K12 : first order transfer from compartment1 to compartment 2;  K21: first order
transfer from compartment 2 to compartment 1; MRT, mean residence time. Cl, clearance;
TABLE 5. MEAN LEVEL OF MANGIFERIN IN RAT RETINA AFTER MANGIFERIN ADMINISTRATION (50 MG/ KG, I.V.). DATA ARE EXPRESSED AS
MEAN±SEM (N=6).
Time (h) Concentration (μg/ml)
0.5 5.69±1.48
1 5.63±1.30
1.5 3.70±1.13
2 3.63±0.06
2.5 2.96±0.31
3.5 1.83±0.06
4.5 1.36±0.02
5.5 0.30±0.02
Detectable mangiferin was found in the eye as shown in Table 5.The mangiferin concentration reached 5.69±1.48 μg/ml 0.5 h
after intravenous administration (50 mg/kg) and then dropped gradually to 0.30±0.02 μg/ml 5.0 h later.
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1665vascular system of the neighboring choroid [21]. Lai et al.
have shown that when 10, 30, and100 mg/kg of mangiferin
was  administered  intravenously,  the  parent  molecule  of
mangiferin was not detected in the brain regions for any of the
dosage treatments. This finding suggested that mangiferin
cannot cross the BBB or is restricted by its detection limit
[17]. Another study by Li et al. [22] proved that mangiferin
could pass through the BBB and showed pharmacological
activity, despite a low level after a single oral dose of 15 g/kg
Rhizoma  anemarrhenae  extract.  Martinez  et  al.  also
demonstrated that mangiferin was able to traverse the BBB
[23]. It has also been shown that mangiferin has real potential
to  ameliorate  the  oxidative  stress  observed  in
neurodegenerative disorders. Mangiferin (20 mg/kg, p.o.) has
been  proven  to  improve  long-term  cholinergic  memory
deficits  by  AChE  inhibition  or  cholinergic  receptor
stimulation and inhibition of NF-κB activation in vivo [24].
All  these  studies  supported  the  fact  that  mangiferin  can
penetrate the BBB and play a protective role in neurologic
diseases. However, whether mangiferin can pass the BRB
remains unknown.
In  contrast  to  the  BRB,  the  BBB  is  established  by
endothelial  cells  rather  than  by  epithelial  cells.  The  BRB
consists of the inner blood–retina barrier (iBRB), which is
formed by elaborate capillaries with barrier characteristics,
and the outer blood–retina barrier (oBRB), which is formed
TABLE 6. PHARMACOKINETIC PARAMETERS OF RETINA FOLLOWING MANGIFERIN ADMINISTRATION (50 MG/KG, I.V.) BY DRUG AND STATISTICS 2.0
Paremeters Unit Average
t1/2α h 1.87±0.40
t1/2β h 1.87±0.40
V1 L/kg 8.14±1.28
CL L/h/kg 2.52±0.38
AUC(0-t) Mg/L·h-1 15.64±1.98
MRT(0-t) h 1.86±0.07
K12 1/h 0.18±0.19
K21 1/h 0.39±0.09
The concentration-time data after single intravenous administration of 50 mg/kg of mangiferin conformed to a two-compartment
model. t1/2(α): distribution half-life; t1/2(β): elimination half-life; V1:Volume of distribution; Cl, clearance; AUC: area under the
plasma concentration–time curve; MRT, mean residence time; K12: first order transfer from compartment1 to compartment 2;
K21: first order transfer from compartment 2 to compartment 1.
Figure 4. Mean level of mangiferin in rat
blood  after  mangiferin  administration
(10, 25, and 50 mg/kg, i.v.). Data are
expressed  as  mean±SEM  (n=6).  The
concentration-time  data  after  a  single
intravenous administration of 10, 25, or
50  mg/kg  showed  that  the  major
parameters  were  correlated  positively
with the dosage given. The mean plasma
concentration–time profile is illustrated
here.
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1666by the retinal pigment epithelium (RPE). The oBRB separates
the neural retina from the fenestrated vascular system of the
neighboring choroid [21]. Studies based on a broad range of
test agents have provided evidence that the epithelial BRB
mirrors  the  pharmacological  properties  of  the  endothelial
BBB to a large extent, and expresses the same major efflux
systems. The permeation ranking of the selected compounds
was similar in the BRB and BBB in vitro system. Our results
showed that mangiferin can be found in the eye, and that the
concentration  in  the  vitrous  went  down  with  the  plasma.
Mangiferin in the retina reached 5.69±1.48 μg/ml 0.5 h after
intravenous administration (50 mg/ kg mangiferin), and the
eye-to-plasma concentration ratio of mangiferin was 2.80%.
Additionally, we have also proven that 5 μg/ml mangiferin
can exert an anti-oxidant effect in the retina (Unpublished
data).
Conclusion: Because of the blood-retina barrier, a study
of whether a drug can reach the target tissue in the eye will
play an important role in illustrating the barrier’s mechanism
and investigating the impact of the drug. The results of the
present study are useful for the administration of mangiferin
in  eye  diseases  and  understanding  mangiferin’s
pharmacokinetic behavior.
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